S&P Futures
4,290.75 -7.50 (-0.17%) Dow Futures
33,824.00 -49.00 (-0.14%) Nasdaq Futures
13,663.00 -18.25 (-0.13%) Russell 2000 Futures
2,021.00 -2.80 (-0.14%) Crude Oil
88.44 -0.97 (-1.08%) Gold
1,794.10 -4.00 (-0.22%)
Hansoh Pharmaceutical Group Company Limited (3692.HK)
Chart Events
Performance Outlook
| Previous Close | 15.880 |
| Open | 15.800 |
| Bid | 15.780 x N/A |
| Ask | 15.800 x N/A |
| Day's Range | 15.700 - 16.060 |
| 52 Week Range | 12.000 - 26.350 |
| Volume | |
| Avg. Volume | 4,439,646 |
| Market Cap | 93.573B |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | 30.98 |
| EPS (TTM) | 0.510 |
| Earnings Date | Mar 30, 2021 |
| Forward Dividend & Yield | 0.09 (0.57%) |
| Ex-Dividend Date | Jun 16, 2022 |
| 1y Target Est | 25.73 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 3692.HK
Related Research
- Newsfile
Kodiak Intersects Shallow Higher-Grade Copper Gold Mineralization in First Holes at Dillard, Confirms Significant Porphyry Target: 0.63% CuEq over 21.0 m, Within 0.23% CuEq over 381.1 m
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - Kodiak Copper Corp. (TSXV: KDK) (OTCQB: KDKCF) (FSE: 5DD1) (the "Company" or "Kodiak") today reports drill results from the 100% owned MPD copper-gold porphyry project in southern British Columbia. Results from the final seven holes drilled at MPD in 2021 are presented in this release. The fully funded 2022 drill program of up to 25,000 metres is now underway.The Company's first two holes testing the ...
- Bloomberg
The Unsung Winners and Biggest Losers of China's Rocky Markets in 2021
(Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac
- GlobeNewswire
Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China
Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unm
